These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29745439)

  • 1. Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans.
    Camilleri M
    Neurogastroenterol Motil; 2018 Sep; 30(9):e13370. PubMed ID: 29745439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases.
    Maselli DB; Camilleri M
    Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1748-1758.e2. PubMed ID: 32673642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids and the gastrointestinal tract.
    Pertwee RG
    Gut; 2001 Jun; 48(6):859-67. PubMed ID: 11358910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased enteric fatty acid amide hydrolase activity is associated with colonic inertia in slow transit constipation.
    Zhang SC; Wang WL; Su PJ; Jiang KL; Yuan ZW
    J Gastroenterol Hepatol; 2014 Feb; 29(2):276-83. PubMed ID: 23926887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids and gastrointestinal motility: animal and human studies.
    Aviello G; Romano B; Izzo AA
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():81-93. PubMed ID: 18924447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids and the Gastrointestinal Tract.
    Camilleri M; Zheng T
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3217-3229. PubMed ID: 37678488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids and intestinal motility: welcome to CB2 receptors.
    Izzo AA
    Br J Pharmacol; 2004 Aug; 142(8):1201-2. PubMed ID: 15277313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.
    Shook JE; Burks TF
    J Pharmacol Exp Ther; 1989 May; 249(2):444-9. PubMed ID: 2542532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.
    Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M
    Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation.
    Camilleri M; Carlson P; McKinzie S; Grudell A; Busciglio I; Burton D; Baxter K; Ryks M; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G13-9. PubMed ID: 17962356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid pharmacology and therapy in gut disorders.
    Uranga JA; Vera G; Abalo R
    Biochem Pharmacol; 2018 Nov; 157():134-147. PubMed ID: 30076849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions.
    Darmani NA
    Methods Mol Med; 2006; 123():169-89. PubMed ID: 16506408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids and the digestive tract.
    Izzo AA; Coutts AA
    Handb Exp Pharmacol; 2005; (168):573-98. PubMed ID: 16596788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids and the gut: new developments and emerging concepts.
    Izzo AA; Sharkey KA
    Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoids and the gut.
    Pinto L; Capasso R; Di Carlo G; Izzo AA
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):333-41. PubMed ID: 12052047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
    Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
    J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
    Sharir H; Abood ME
    Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
    Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
    Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cannabinoid receptors in the control of gastrointestinal motility and perception.
    Fioramonti J; Bueno L
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):385-97. PubMed ID: 19072387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.